机译:Gilteritinib,FLT3 / AXL抑制剂,显示FLT3突变急性髓性白血病小鼠模型中的抗血清血肿活性
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Astellas Res Technol Co Ltd Pharmacol Res Div 21 Miyukigaoka Tsukuba Shi Japan;
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Astellas Pharma Inc Res Program Management Off Drug Discovery Res 21 Miyukigaoka Tsukuba Shi;
Acutemyeloidleukemia; Fms-liketyrosinekinase 3; Mutation; Protein kinase inhibitors; Xenograft antitumor assays;
机译:Gilteritinib,FLT3 / AXL抑制剂,显示FLT3突变急性髓性白血病小鼠模型中的抗血清血肿活性
机译:多中心,开放标签,3臂研究Gilteritinib,Gilteritinib加氮杂氨酸,或仅在新诊断的FLT3突变(FLT3(MUT +))急性髓性白血病(AML)患者中没有资格对强化诱导化疗的患者:从安全队列中发现
机译:含有FLT3-ITD突变的翻倒急性髓性白血病患有FLT3-ITD突变的铱型核糖肉瘤,用Gilteritinib,FLT3抑制剂治疗
机译:串联质谱表征第二代FLT3抑制剂Quizartinib的相关物质,用于髓性白血病的抗癌化合物
机译:FLT3抑制剂对FLT3-ITD突变急性髓性白血病标准治疗的比较
机译:Gilteritinib一种FLT3 / AXL抑制剂在FLT3突变的急性髓性白血病小鼠模型中显示抗白血病活性
机译:Bcl-2的抑制在FLT3突变的急性髓性白血病的临床前模型中协同增强中豚鼠和Gilteritinib的抗血尿血肿活性